MESO vs. BBIO, LNTH, TGTX, LEGN, AXSM, TLX, BPMC, KRYS, NUVL, and CYTK
Should you be buying Mesoblast stock or one of its competitors? The main competitors of Mesoblast include BridgeBio Pharma (BBIO), Lantheus (LNTH), TG Therapeutics (TGTX), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Krystal Biotech (KRYS), Nuvalent (NUVL), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry.
Mesoblast vs.
BridgeBio Pharma (NASDAQ:BBIO) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations, community ranking and profitability.
In the previous week, BridgeBio Pharma had 18 more articles in the media than Mesoblast. MarketBeat recorded 21 mentions for BridgeBio Pharma and 3 mentions for Mesoblast. Mesoblast's average media sentiment score of 1.02 beat BridgeBio Pharma's score of 1.01 indicating that Mesoblast is being referred to more favorably in the news media.
Mesoblast received 239 more outperform votes than BridgeBio Pharma when rated by MarketBeat users. However, 71.90% of users gave BridgeBio Pharma an outperform vote while only 70.36% of users gave Mesoblast an outperform vote.
BridgeBio Pharma has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Mesoblast has a beta of 3.4, suggesting that its stock price is 240% more volatile than the S&P 500.
Mesoblast has lower revenue, but higher earnings than BridgeBio Pharma.
BridgeBio Pharma currently has a consensus target price of $52.90, indicating a potential upside of 45.33%. Mesoblast has a consensus target price of $18.00, indicating a potential upside of 35.34%. Given BridgeBio Pharma's higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Mesoblast.
Mesoblast has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -241.44%.
99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 24.7% of BridgeBio Pharma shares are held by insiders. Comparatively, 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Mesoblast beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.
Get Mesoblast News Delivered to You Automatically
Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mesoblast Competitors List
Related Companies and Tools
This page (NASDAQ:MESO) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy MESO Stock Free MESO Stock Alerts